Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib versus etanercept for NSAID tapering and corticosteroid de-escalation in active rheumatoid arthritis
2018-004539-54Phase 4Completed
- Sponsor
- Fraunhofer Institute for Translational Medicine and Pharmacology
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tofacitinib, etanercept and celecoxib in rheumatoid arthritis (RA) (2 arms), sponsored by Fraunhofer Institute for Translational Medicine and Pharmacology. Primary endpoint: Discontinuation of celecoxib with clinically relevant pain improvement at week 12. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2018-004539-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004539-54.